Safety and Immunogenicity of Repeated Doses of ABvac40 in Patients With a-MCI or Vm-AD

NCT03461276 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

134

Enrollment

INDUSTRY

Sponsor class

Conditions

Mild Cognitive Impairment
Alzheimer Disease

Interventions

BIOLOGICAL: ABvac40
BIOLOGICAL: Placebo

Sponsor

Araclon Biotech S.L.